{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T09:44:39Z","timestamp":1790934279612,"version":"4.1.0"},"reference-count":28,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"17","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO"],"published-print":{"date-parts":[[2019,6,10]]},"abstract":"<jats:sec>\n                    <jats:title>PURPOSE<\/jats:title>\n                    <jats:p>Anti\u2013programmed death-1 (PD-1) monotherapy induces a high response rate in patients with relapsed\/refractory classic Hodgkin lymphoma (cHL), but complete remission (CR) is infrequently observed. As decitabine is known to boost T-cell function, we assessed the safety and efficacy of anti\u2013PD-1 camrelizumab alone versus decitabine-primed camrelizumab in patients with relapsed\/refractory cHL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>This two-arm, open-label, phase II study enrolled patients with relapsed\/refractory cHL who had received at least two lines of previous therapy. Anti\u2013PD-1 treatment-na\u00efve patients were randomly assigned (1:2) to camrelizumab (200 mg) monotherapy or decitabine (10 mg\/d, days 1 to 5) plus camrelizumab (200 mg, day 8) combination therapy every 3 weeks. Patients who were previously treated with anti\u2013PD-1 were assigned combination therapy. Primary end point was CR rate and safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>Overall, 86 patients were enrolled and evaluated for response, with a median follow-up of 14.9 months. In anti\u2013PD-1\u2013na\u00efve patients, CR rate was 32% (six of 19 patients) with camrelizumab monotherapy versus 71% (30 of 42 patients) who were administered decitabine plus camrelizumab ( P = .003). At the time of analysis, the response duration rate at 6 months was 76% on camrelizumab monotherapy versus 100% on decitabine plus camrelizumab. For patients who were previously treated with anti\u2013PD-1, 28% achieved CR and 24% partial response after decitabine plus camrelizumab. Ten patients maintained a response at more than 6 months and 81% of responders were estimated to have a response at more than 1 year. For both treatments, the most common adverse events were clinically inconsequential cherry hemangiomas and leukocytopenia that were self-limiting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>CR rate in patients with relapsed\/refractory cHL who were clinically na\u00efve to PD-1 blockade was significantly higher with decitabine plus camrelizumab than with camrelizumab alone. Decitabine plus camrelizumab may reverse resistance to PD-1 inhibitors in patients with relapsed\/refractory cHL.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/jco.18.02151","type":"journal-article","created":{"date-parts":[[2019,4,30]],"date-time":"2019-04-30T15:59:53Z","timestamp":1556639993000},"page":"1479-1489","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":183,"title":["Addition of Low-Dose Decitabine to Anti\u2013PD-1 Antibody Camrelizumab in Relapsed\/Refractory Classical Hodgkin Lymphoma"],"prefix":"10.1200","volume":"37","author":[{"given":"Jing","family":"Nie","sequence":"first","affiliation":[{"name":"Chinese People\u2019s Liberation Army General Hospital, Beijing, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunmeng","family":"Wang","sequence":"additional","affiliation":[{"name":"Chinese People\u2019s Liberation Army General Hospital, Beijing, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[{"name":"Chinese People\u2019s Liberation Army General Hospital, Beijing, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingming","family":"Yang","sequence":"additional","affiliation":[{"name":"Chinese People\u2019s Liberation Army General Hospital, Beijing, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Mei","sequence":"additional","affiliation":[{"name":"Chinese People\u2019s Liberation Army General Hospital, Beijing, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Dong","sequence":"additional","affiliation":[{"name":"Chinese People\u2019s Liberation Army General Hospital, Beijing, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Li","sequence":"additional","affiliation":[{"name":"Chinese People\u2019s Liberation Army General Hospital, Beijing, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiejie","family":"Liu","sequence":"additional","affiliation":[{"name":"Chinese People\u2019s Liberation Army General Hospital, Beijing, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjing","family":"Ku","sequence":"additional","affiliation":[{"name":"Chinese People\u2019s Liberation Army General Hospital, Beijing, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Chinese People\u2019s Liberation Army General Hospital, Beijing, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meixia","family":"Chen","sequence":"additional","affiliation":[{"name":"Chinese People\u2019s Liberation Army General Hospital, Beijing, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojing","family":"An","sequence":"additional","affiliation":[{"name":"Chinese People\u2019s Liberation Army General Hospital, Beijing, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Shi","sequence":"additional","affiliation":[{"name":"Chinese People\u2019s Liberation Army General Hospital, Beijing, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malcolm V.","family":"Brock","sequence":"additional","affiliation":[{"name":"John Hopkins University, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Bai","sequence":"additional","affiliation":[{"name":"Chinese People\u2019s Liberation Army General Hospital, Beijing, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weidong","family":"Han","sequence":"additional","affiliation":[{"name":"Chinese People\u2019s Liberation Army General Hospital, Beijing, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.53.1194"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21438"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.0410"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-02-699850"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411087"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30167-X"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.72.1316"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.66.4482"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-1387"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.06.007"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf2807"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2014.08.010"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2011.12.029"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.5.956"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-016-0363-1"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30495-9"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-2439"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.8800"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymeth.2014.08.016"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.0793"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.183.183"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-10-811224"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-01-761346"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.67.3467"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1126\/science.aae0491"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.9352"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-1201"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.3677"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.18.02151","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,29]],"date-time":"2022-05-29T05:39:28Z","timestamp":1653802768000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.18.02151"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,10]]},"references-count":28,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2019,6,10]]}},"alternative-id":["10.1200\/JCO.18.02151"],"URL":"https:\/\/doi.org\/10.1200\/jco.18.02151","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,10]]},"assertion":[{"value":"2019-03-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-04-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}